Case 1:20-cv-00393-LMB-WEF Document 1462-8 Filed 04/05/23 Page 1 of 3 PageID# 39620
`
`Exhibit 8
`
`

`

`Case 1:20-cv-00393-LMB-WEF Document 1462-8 Filed 04/05/23 Page 2 of 3 PageID# 39621
`
`Transcripts
`
`Consumer
`
`Philip Morris International Inc. (PM) Q3 2021
`Results - Earnings Call Transcript
`
`Oct. 19, 2021 1:22 PM ET | Philip Morris International Inc. (PM) | 1 Like
`
`SA Transcripts
`130.26K Followers
`
`Q3: 2021-10-19 Earnings Summary
`
`Play Call
`
`Slides
`
`10-Q
`
`EPS of $1.58 beats by $0.02 | Revenue of $8.12B (9.08% Y/Y) beats by $175.15M
`
`Philip Morris International Inc. (NYSE:PM) Q3 2021 Earnings Conference Call October
`19, 2021 9:00 AM ET
`
`Company Participants
`
`Nicholas Rolli – Vice President of Investor Relations
`
`Emmanuel Babeau – Chief Financial Officer
`
`Conference Call Participants
`
`Gaurav Jain – Barclays
`
`Bonnie Herzog – Goldman Sachs
`
`Pamela Kaufman – Morgan Stanley
`
`Vivien Azer – Cowen
`
`Chris Growe – Stifel
`
`Callum Elliott – Bernstein
`
`

`

`Following the success, we plan to launch in our second market of Switzerland next
`Case 1:20-cv-00393-LMB-WEF Document 1462-8 Filed 04/05/23 Page 3 of 3 PageID# 39622
`month and look forward to additional major launches in 2022 when circumstances allow.
`We continue to commercialize IQOS VEEV with good progress in the first group of
`markets, where we started in our own channels with a limited range of taste variants
`and nicotine levels.
`
`IQOS VEEV is a premium product, providing a superior experience. And the
`commercial infrastructure of IQOS allows it to deploy efficiently and at scale through a
`bespoke route-to-market approach. As we start to expand distribution and the
`consumable offering, we see sign of increased uptake and clear positive consumer
`feedback related to competitive products. We see encouraging early success in Italy
`where VEEV reached an estimated 7% national exit volume of tech share of crude
`system product -- system put, sorry, despite not yet being available nationally.
`
`And in the Czech Republic with an estimated 8% national volume of tech exit share. We
`also launched in Croatia in Q3, Canada in October, and plan to launch in Ukraine
`before year-end. We also continue preparations to apply for a PMTA from the U.S. FDA
`in the second half of 2022. Turning now to our strategy to moving to new business
`areas beyond tobacco and nicotine, which focuses on leveraging and complementing
`our existing capabilities in the health care and wellness space. We see significant
`opportunity in adjacent area with our two focused corridors of self-care wellness,
`including botanicals and inhaled therapeutics, expected to have an addressable market
`of around $65 billion by 2025.
`
`The acquisitions of Fertin Pharma, Otitopic, and Vectura enabled us to more rapidly
`expand our development capabilities with over 250 scientists, infrastructure, technology,
`and expertise in innovative enameled and oral product formulation while continuing to
`grow CDMO activities.
`
`As shown on this slide, this opens up a number of highly complementary opportunities
`and new focus areas. This acquisition will fully leverage PMI 's existing capability like
`science, product innovation, and clinical expertise related to innovation. We look
`forward to updating you more in the future on our plans and progress in these exciting
`new areas. Moving to sustainability and our ESG priorities, we continue to make good
`progress throughout our [Indiscernible] through advancing our transformation and
`addressing our most material impact on society.
`
`